GKOS (Glaukos Corporation) Short-Term Debt to Capital

Corporate company logo of Glaukos Corporation (GKOS)

Glaukos Corporation (GKOS) is protected by exclusive patents for microstents and maintains a powerful influence in ophthalmology under strict FDA oversight. This price chart on GURU.Markets shows the shares demonstrating a metric of 0.00. The business relies on advanced engineering of miniature implants for glaucoma therapy. The company is currently implementing the iDose TR system, radically updating global standards for microsurgical intervention in the ocular environment.

Ratio of Short-Term Indebtedness to Capital: Glaukos Corp. (GKOS) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Glaukos Corporation

- stock quotes and analyst forecast:
Stock Price Glaukos Corp.|GKOS - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Glaukos Corp|GKOS - Enterprise Value
- book capitalization information:
Net Assets per Single Share Glaukos|GKOS - Accounting Value of Company|Market Value to Book Value Ratio glaukos.com|GKOS - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Glaukos Corporation|GKOS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Glaukos|GKOS - Aggregate Debt Obligations|Debts to Book Capitalization Glaukos Corp|GKOS - Long-Term Debt|Company Current Liabilities Glaukos|Quick Ratio glaukos.com
- company profitability and valuation multiples indicators:
GKOS - Company Net Income
Fundamental valuation:Glaukos Corp.
Brand item of Glaukos Corp

The high-tech status of Glaukos Corporation (GKOS) as a leader in glaucoma therapy ensures strong market resilience, which is reflected in the current value of 0.00. By analyzing changes in short-term debt relative to equity, an investor can track the daily price action of short-term liabilities (up to one year), allowing for the rapid diagnosis of liquidity risks and confirmation of the fundamental reliability of the company's financing structure.

Competitors of Glaukos Corporation (GKOS)

Short-Term Debt to Capital ALC|BLCO (Bausch Health) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital APLS (Apellis Pharmaceuticals)|Short-Term Debt to Capital Belite Bio Pharma BLTE|OCUL - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital HROW (Harrow Inc)|Viridian Pharma (VRDN) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio LENZ Corp|OCS (Oculis Holding) - Short-Term Debt to Capital|Short-Term Debt to Capital eyepointpharma.com|Short-Term Debt to Equity Ratio KOD (Kodiak Sciences)|ALDX (aldeyra.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital KALA (KALA BIO)|Opus Genetics, Inc. (IRD) - Current Liabilities to Capital|OKYO: Short-Term Debt to Equity Ratio|Current Liabilities to Capital Adverum Biotechnologies|OTLK: Short-Term Debt to Capital|Current Liabilities to Capital Clearside Biomedical Inc (CLSD)|Short-Term Debt to Equity NovaBay Pharmaceuticals Inc.|Kiora Pharma (KPRX) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital ALIM|eyenovia.com (EYEN) - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Guardion Health Sciences GHSI|Ocuphire Pharma Inc - Short-Term Debt to Equity|Opthea Ltd. - Short-Term Debt to Capital